COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION | ||||
| ALEXMED ePosters | ||||
| Article 1, Volume 4, Issue 1, March 2022, Page 24-25 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2022.120548.1364 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ashraf Ghandor1; Dalia Nafea2; Mona Wagdy Helmy3; Essam Abdel Mohsen4; Soha Adel Ellhakim  5
| ||||
| 1Department of Internal Medicine (Hematology Unit) Faculty of Medicine, University of Alexandria, Egypt | ||||
| 2Department of Hematology, Alexandria University | ||||
| 3Department of Clinical and Chemical Pathology, Faculty of Medicine Alexandria University | ||||
| 4Hematology Unit At Elmaadi Military Hospital | ||||
| 5Departments of Internal Medicine (Hematology Unit) Faculty of Medicine, University of Alexandria, Egypt | ||||
| Abstract | ||||
| ALL is primarily a disease of childhood, with 75% of cases occurring in children under the age of 10 years at diagnosis. However, although ALL is rare in adults, there is an increasing incidence with age after the age of 40 years. Eighty – five percent of cases are of B– cell lineage and have an equal sex incidence; there is a male predominance for the 15% of T - cell ALL.1 The clinical presentation of ALL is nonspecific, and thus, patients may present with “B symptoms”, infection, easy bruising / bleeding, dyspnea, and fatigue.2 The diagnosis of ALL requires the presence of 20% or more lymphoblasts in the bonemarrow. Further assessment by flow cytometry, morphological studies, immunophenotyping, and cytogenetic testing is important. The primary goal of induction therapy is complete eradication of lymphoblasts from the blood, bone marrow, CNS and other extramedullary sites when initially involved. Complete remission (CR) is currently defined on a morphological basis of less than 5% blasts in the bone marrow in the presence of over allhaematological recovery (neutrophils > 1.0 × 109 /L, platelets > 100 × 109/L).3 | ||||
| Keywords | ||||
| CALGB; DFCI; CR | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 95 |
||||
